Tessera
Folgen

Chris Ashwood

@cashwood.proteaglyco.com

Director of Protea Glycosciences Accelerating glycoscience research

1775 Posts1506 Follower966 Folgt
Ben Lehner@benlehner.bsky.social · 2d ago

1st genome sequenced (Sanger 1977), 1st genome synthesised (Venter 2003), 1st genome + proteome fully mutated (Huijin Xiangua 2026!) @crg.eu @sangerinstitute.bsky.social Complete Mutagenesis of the Genome and Proteome of ΦX174 www.biorxiv.org/content/10.6...

Complete Mutagenesis of the Genome and Proteome of ΦX174

The bacteriophage ΦX174 was the first genome to be sequenced and the first to be chemically synthesised. Here we present a complete map of the consequences of changing every nucleotide in the ΦX174 ge...

biorxiv.org

Erin Humphries@erinmhumphries.bsky.social · 4d ago

Thanks for sharing my preprint! www.linkedin.com/posts/erin-m...

Happy to share my first preprint which closes another chapter of my PhD thesis. This work demonstrates that FFPE tissues retain biologically meaningful phosphorylation signalling, creating a robust… |...

Happy to share my first preprint which closes another chapter of my PhD thesis. This work demonstrates that FFPE tissues retain biologically meaningful phosphorylation signalling, creating a robust fr...

linkedin.com

Kermit Murray@kkmurray.bsky.social · 5d ago

(BioRxiv All) An organ-resolved rat FFPE phosphoproteome map enables directional kinase activity inference: Formalin fixed paraffin embedded (FFPE) tissue is the dominant clinical pathology resource yet whether it faithfully preserves organ signalling biology and supports… #BioRxiv #MassSpecRSS

Will Fondrie@willfondrie.com · 6d ago

New @talusbio.bsky.social #AI preprint just dropped 🚀 Meet Ptarmigan-1. It predicts which small molecules bind a protein, and which residues they hit, from sequence and 2D chemistry alone. No structures, no docking, no poses. www.biorxiv.org/content/10.6... Time for a 🧵 (1/13)

Structure-free, site-resolved contrastive learning extends small-molecule discovery beyond the reach of structure-based modeling

Virtual screening asks which molecules, among an enormous space of drug-like chemistry, are worth synthesizing and testing against a protein target. Most modern methods answer by building and scoring ...

biorxiv.org

PastelBio@pastelbio.bsky.social · last wk.

OK folks – decision made. I’m spending too much time following all things proteomics and need to move on to pastures new – Immunodiagnostics. Pastel’s website will be available until it’s renewal in 5months time. 1/3

Laurel Oldach@laureloldach.bsky.social · last wk.

Molecular aging is a really interesting field - it's not just cell systems, but long-lived proteins themselves that accumulate damage over time. This start-up is trying to remove advanced glycation end products from proteins like collagen in the extracell matrix. cen.acs.org/biological-c...

Enzyme engineers tackle protein damage from aging

By undoing lysine glycation, Revel Pharmaceuticals hopes to address tissue stiffness, inflammation

cen.acs.org

Alan Cartmell@acartmell47.bsky.social · last wk.

Delighted to have this collaborative work out in @natmicrobiol.nature.com on how A. muciniphila deploys its sulfatases, both their localisation and substrate specificity, to metabolise colonic mucin www.nature.com/articles/s41... #glycotime.

Unique adaptations in sulfatases underpin colonic mucin degradation by Akkermansia muciniphila - Nature Microbiology

Structural and biochemical follow-up of a serendipitous discovery reveals that Akkermansia muciniphila carbohydrate sulfatases are uniquely adapted to digest colonic mucins in collaboration with other...

nature.com

Vivek Mutalik@vivekmutalik.bsky.social · 2w ago

Surface architecture of the bacterial envelope determines phage adsorption route in pathogenic Escherichia coli O157:H7 www.biorxiv.org/content/10.6...

Surface architecture of the bacterial envelope determines phage adsorption route in pathogenic Escherichia coli O157:H7

The outermost surface layers of Gram-negative bacteria determine phage access to terminal receptors, yet their genetic basis has been mapped almost exclusively in laboratory strains that lack them. He...

biorxiv.org

Cermav - UPR 5301@cermav.bsky.social · 2w ago

Breaking news ! The « Foundations of Polysaccharide Science » book is out ! Serge Pérez has just published an e-book titled "Foundations of Polysaccharide Science" with Taylor & Francis (CRC Press). More information ➡️ cermav.cnrs.fr/en/foundatio... @cnrs.fr

« Foundations of Polysaccharide Science » book - Centre de recherches sur les macromolécules végétales

Serge Pérez, CNRS Emeritus Research Director at Cermav, has just published an e-book titled Foundations of Polysaccharide Science with Taylor & Francis (CRC Press). The book outlines the origins and natural sources of polysaccharides in plants, animals, fungi, bacteria, and algae. It describes the biosynthetic pathways and functional modifications of these molecules for a variety […]

cermav.cnrs.fr

Carl T. Bergstrom@carlbergstrom.com · 2w ago

8. We imagine the scientists taking their work through the following lifecycle. Initially the value of a project is unknown. After a discovery period, the value is revealed. Scientists then can abandon the project and start over, or choose how thoroughly to develop it before publication.

Model diagram. First, a discovery phase of length s leads to a decision "back to the drawing board" or "let's do this". If the latter is chosen, there is a development phase of length a+b before success.
Kermit Murray@kkmurray.bsky.social · 2w ago

(BioRxiv All) Ablation of GM3 Gangliosides in cardiomyocytes modestly impacts heart size but does not protect the murine heart against ischemia reperfusion injury: Advances in mass spectrometry have seen the identification of hundreds of new lipid species, some of which have… #BioRxiv #MassSpecRSS

Ablation of GM3 Gangliosides in cardiomyocytes modestly impacts heart size but does not protect the murine heart against ischemia reperfusion injury

Advances in mass spectrometry have seen the identification of hundreds of new lipid species, some of which have been found to be associated with adverse cardiac remodeling. Key among these are GM3 gangliosides, which have been associated with metabolic disease, and more recently, adverse cardiac remodeling. Whether GM3s have a direct pathophysiological effect in the heart remains unclear. The present study investigated the effects of cardiomyocyte-specific knockout of GM3 synthase (GM3S, enzyme responsible for the synthesis of GM3) in the heart under basal settings and in response to ischemia-reperfusion (I/R) injury. A new cardiomyocyte-specific GM3S knockout (KO) model was generated, with knockout confirmed via lipidomic profiling. Under basal conditions, male GM3SKO mice exhibited reduced heart weight to tibia length (HW/TL) ratios with no evidence of pathological remodeling, while female mice showed no significant morphological differences. Male GM3SKO mice subjected to 1 hour ischemia and 4 weeks reperfusion demonstrated reduced HW/TL ratio compared to control mice subjected to I/R. However, no significant differences were observed in cardiac function, heart failure and fibrotic markers. Lipidomic profiling (49 classes, ~850 species) revealed significant accumulation of dihexosylceramide, a metabolic precursor of GM3 in the male heart under basal and post-I/R conditions. In male GM3SKO I/R hearts, GM3 reduction was associated with decreases in odd- and branch-chained phospholipids, together with distinct changes in circulating ether lipid species. Collectively, cardiomyocyte-specific GM3 depletion contributed to sphingolipid remodeling but did not confer protection against I/R-mediated injury. These findings suggest that elevated GM3 levels observed in settings of cardiac pathology are not cardiomyocyte driven, highlighting the importance of understanding cell-type specific contributions to adverse cardiac remodeling.

dlvr.it

Akul Mehta@akulmehta.bsky.social · 3w ago

Excited to share our new paper on our latest technology development: GlycoStrips Full paper open access: www.cell.com/trends/biote... #glycotime #glycobiology #pointofcare #diagnostics #immunemonitoring #immunity #antibodies #glycans

Point-of-care GlycoStrips detect serum and salivary antibodies to blood group antigens and pathogens

We present the development of GlycoStrip, which is a multiplex anti-glycan antibody analysis platform. GlycoStrip incorporates neoglycoproteins and other materials directly printed on nitrocellulose s...

cell.com

Chris Ashwood@cashwood.proteaglyco.com · 3w ago

Neu5Gc is reported at trace levels in human samples, but whether it is detected depends heavily on the assay. We built a multi-site benchmark to define where Neu5Gc-bearing N-glycans can be identified and quantified reliably. #glycotime We describe this in our new preprint: doi.org/10.64898/202...

Development of a Matrix-Matched Calibration Curve for Multi-Site Quantification of Neu5Gc-Bearing N-Glycans

N-glycolylneuraminic acid (Neu5Gc) has been repeatedly associated with human cancer, but reliable detection has remained elusive, generating controversy regarding its presence in human samples. To add...

doi.org

Chris Ashwood@cashwood.proteaglyco.com · 3w ago

Big trouble in a nano world. It has been building up to this since the Nanomics preprint was disclosed that "heavily borrowed" elements from the Seer Astral marketing product notes. I'm not a lawyer, but Seer has the most compelling case thus far.

"On May 28, 2026, Seer, Inc. and The Brigham and Women's Hospital, Inc. (collectively “Seer”) filed a complaint with the U.S. International Trade Commission (“ITC”), alleging that Nanomics Biotechnology Co., Ltd. (“Nanomics”) infringes five different Seer patents. The complaint was filed without proper due diligence by Seer and is based in critical aspects on articles describing an experimental product that was never sold in the United States rather than Nanomics’ actual commercial products. Nanomics categorically rejects Seer’s baseless allegations of patent infringement. Nanomics’ actual products imported to the U.S. are fundamentally different from Seer’s patents. As described by Seer itself in its ITC Complaint, what Seer purported to invent was “combining multiple, non-specific nanoparticles, each with different physicochemical properties, to capture and analyze the results from the resulting protein coronas.” In contrast, Nanomics uses a single particle approach which is completely distinct from Seer’s patents. Nanomics also does not infringe any valid claims of one of Seer’s patents describing a mass spectrometer coupled to a proteomics sample preparation device. Nanomics has developed its own proprietary proteomics products which have been well-received in the U.S. market and have distinct advantages over Seer’s products. Nanomics views Seer’s allegations as nothing more than a misguided attempt by Seer to divert the attention of shareholders and the public from Seer’s severe value reduction— including an approximately 97% decline in shareholder return since its IPO​ and hundreds of millions of dollars in cumulative net losses​ reported in its SEC filings. It is regrettable that Seer has resorted to litigation instead of fair competition in the marketplace, rejecting a reasonable path to resolution and choosing to further burn shareholder money on a meritless case that does nothing to improve the company’s product competitiveness and only worsens its finan…
Tine Claeys@tineclaeys.bsky.social · 3w ago

Our first HUPO Single Cell Initiative benchmarking study is out! 🎉 7 labs, 2 continents, 2 instrument platforms, 6 DIA tools - working toward reproducible, comparable single-cell proteomics. Code + processed data available now, raw data coming soon.

Defining Quality Control Standards for Single-Cell Proteomics by Inter-Laboratory Benchmarking

Single-cell proteomics can quantify thousands of proteins from individual mammalian cells, yet the absence of community-wide quality control limits biological interpretability. Here, the HUPO Single C...

biorxiv.org